# Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

> **NCT06425133** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 174 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **PROCEDURE:** Blood sample
- **OTHER:** Quality of life questionnaires
- **PROCEDURE:** Biopsy
- **DRUG:** Regorafenib
- **COMBINATION_PRODUCT:** Regorafenib + metronomic chemotherapy

## Key facts

- **NCT ID:** NCT06425133
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2027-09
- **Final completion:** 2028-09
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06425133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06425133, "Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06425133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*